✦ LIBER ✦

A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer : A Trial of the NCIC Clinical Trials Group

✍ Scribed by Scott A. Laurie; Lillian L. Siu; Eric Winquist; Andrew Maksymiuk; Erica L. Harnett; Wendy Walsh; Dongsheng Tu; Wendy R. Parulekar

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 147 KB
Volume: 116
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.24745

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of gemcitabine in patient

Phase II trial of gemcitabine in patients with advanced sarcomas (E1797) : A trial of the Eastern Cooperative Oncology Group

✍ Scott Okuno; Louise M. Ryan; John H. Edmonson; Dennis A. Priebat; Ronald H. Blum 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 2 views

## Abstract ## BACKGROUND The current study was conducted to evaluate the antitumor activity and toxicity of gemcitabine in patients with advanced sarcoma. ## METHODS Twenty‐five patients with advanced sarcomas, who previously were untreated for metastatic disease, were treated on an Eastern Coo

Phase 2 trial of sorafenib in patients w

Phase 2 trial of sorafenib in patients with advanced urothelial cancer : A Trial of the Eastern Cooperative Oncology Group

✍ Robert Dreicer; Hailun Li; Mark Stein; Robert DiPaola; Michael Eleff; Bruce J. R 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 2 views

Phase II trial of gemcitabine and doceta

Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium : A trial of the Eastern Cooperative Oncology Group

✍ Robert Dreicer; Judith Manola; Daniel J. Schneider; John F. Schwerkoske; Christo 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB 👁 2 views

## Abstract ## BACKGROUND Gemcitabine and docetaxel are active agents in advanced urothelial carcinoma. A Phase II trial of this combination was performed to determine the activity and toxicity of these agents in a multiinstitutional setting in patients previously treated with one prior chemothera

Phase 2 trial of pemetrexed disodium and

Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802) : A trial of the Eastern Cooperative Oncology Group

✍ Robert Dreicer; Hailun Li; Matthew M. Cooney; George Wilding; Bruce J. Roth 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 2 views

## Abstract ## BACKGROUND. There is a need to identify active new regimens in patients with advanced urothelial cancer. Pemetrexed and gemcitabine are active agents in advanced urothelial cancer. A phase 2 trial of the combination of these 2 agents was performed in patients with advanced urothelia

Molecular predictors of outcome in a pha

Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer : National Cancer Institute of Canada Clinical Trials Group Study PA.3

✍ Gilda da Cunha Santos; Neesha Dhani; Dongsheng Tu; Kayu Chin; Olga Ludkovski; Su 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 311 KB 👁 2 views

Gemcitabine, dexamethasone, and cisplati

Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma : A Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG)

✍ Michael Crump; Tara Baetz; Stephen Couban; Andrew Belch; Deborah Marcellus; Kang 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB